Cargando…

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway

High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy. However, the molecular mechanisms underlying HGSOC development, progression, chemotherapy insensitivity and resistance remain unclear. Two independent GEO datasets, including the gene expression profile of primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Gonghua, Ma, Hanlin, Li, Yingwei, Peng, Jiali, Chen, Jingying, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651821/ https://www.ncbi.nlm.nih.gov/pubmed/34876569 http://dx.doi.org/10.1038/s41419-021-04429-6

Ejemplares similares

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
por: Ma, Hanlin, et al.
Publicado: (2019)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
por: Liu, Yixuan, et al.
Publicado: (2021)

PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway
por: Ma, Hanlin, et al.
Publicado: (2023)

TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt‐mTOR pathway
por: Huang, Hongxia, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2014)

Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway
por: Wang, Peng, et al.
Publicado: (2022)

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer
por: Andorfer, Peter, et al.
Publicado: (2016)

FBLN5 is targeted by microRNA-27a-3p and suppresses tumorigenesis and progression in high-grade serous ovarian carcinoma
por: Li, Rongrong, et al.
Publicado: (2020)

Tubal Origin of “Ovarian” Low-Grade Serous Carcinoma: A Gene Expression Profile Study
por: Wang, Yiying, et al.
Publicado: (2019)

Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2016)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

AMPK/mTOR Signaling in Autophagy Regulation During Cisplatin-Induced Acute Kidney Injury
por: Wang, Ying, et al.
Publicado: (2020)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
por: Yu, Jian, et al.
Publicado: (2022)

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
por: Chen, Zhongshao, et al.
Publicado: (2022)

mTOR Pathways in Cancer and Autophagy
por: Paquette, Mathieu, et al.
Publicado: (2018)

Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
por: Duan, Jingya, et al.
Publicado: (2023)

Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway
por: Jiang, Shaoyan, et al.
Publicado: (2019)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway
por: Wu, Tao, et al.
Publicado: (2015)

Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism
por: Luo, Lifang, et al.
Publicado: (2021)

The mTOR–Autophagy Axis and the Control of Metabolism
por: Deleyto-Seldas, Nerea, et al.
Publicado: (2021)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer
por: Noriega-Rivera, Ricardo, et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
por: Jin, H-O, et al.
Publicado: (2012)

Targeted Inhibition of mTOR Signaling Improves Sensitivity of Esophageal Squamous Cell Carcinoma Cells to Cisplatin
por: Hou, Guiqin, et al.
Publicado: (2014)

miR-7 Increases Cisplatin Sensitivity of Gastric Cancer Cells Through Suppressing mTOR
por: Xu, Ning, et al.
Publicado: (2017)

MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
por: Xu, Shaohua, et al.
Publicado: (2015)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l2o2nr4f9v39g41r6b5g82a0n5